Showing 12 RESULTS FOR
New Study Used Personalized Goals to Assess Treatment Effectiveness for Patients with Major Depressive Disorder
Results from an open-label study evaluating the development and assessment of personalized goals as a way of measuring treatment effectiveness in MDD.
New Data Added to TRINTELLIX® (vortioxetine) Labeling Demonstrated Superiority Over Escitalopram in Improving SSRI-Induced Sexual Dysfunction in Patients with Major Depressive Disorder
TRINTELLIX® is the first antidepressant to include head-to-head data in its labeling that showed improvement in treatment-emergent sexual dysfunction in patients with MDD who switched from certain SSRI treatments.
Video: No Stone Unturned in Mental Health Research
By Doug Williamson, MD
In this video, Dr. Doug Williamson, Lundbeck's Chief Medical Officer and VP of US Medical, discusses putting patients at the center of drug R&D and how Lundbeck is leaving no stone unturned in pursuit of new treatment options.
Fighting Suicide in our Communities, Workplaces and Research Labs
By Peter Anastasiou
As a leader of a company dedicated to helping people living with psychiatric disorders, Lundbeck's Peter Anastasiou is passionate about the need to fight stigma and raise awareness about suicide prevention. In this opinion piece, Peter shares what Lundbeck is doing to combat suicide.
Trintellix Prescribing Information Updated to Include New Data Showing Improvement in Processing Speed
Takeda Pharmaceutical Company Limited and H. Lundbeck A/S announced the U.S. Food and Drug Administration (FDA) approved a supplemental new drug application for TRINTELLIX® (vortioxetine). The FOCUS and CONNECT studies showed TRINTELLIX had a positive effect on processing speed, an important aspect of cognitive function that may be impaired in adult patients with acute MDD.